You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》德琪医药(06996.HK)超购近264倍上限定价 一手中签率20%
阿思达克 11-19 08:41
专注於创新抗肿瘤药物的亚太地区临床阶段生物制药公司德琪医药(06996.HK)公布招股结果显示,发售价定於18.08元,为上限定价(招股价介乎15.8至18.08元),公开发售录超购263.76倍,经重新分配後,公开发售股数由10%增至50%。每手500股,中签率为20%。该股将於明日(20日)挂牌上市。高盛及摩根大通为联席保荐人、联席全球协调人、联席账簿管理人及联席牵头经办人。

公司预期集资净额26.36亿元,当中41%将分配予集团的核心产品;25%将用於为集团其他四个临床阶段候选药物提供资金;9%用於管线中的其他临床前候选药物正在进行的临床前研究及计划进行的临床试验;14%用於扩大其研发管线,包括发现新的候选药物及业务开发活动;余下1%及10%分别用於资本开支及一般公司用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account